India grants Pfizer patent for pneumonia vaccine
Pneumococcal Conjugate Vaccine is used for the prevention of pneumococcal pneumonia and invasive diseases caused by 13 Streptococcis pneumoniae strains.
India in August 2017 granted US pharmaceutical company Pfizer Inc. a patent for its pneumonia vaccine Prevnar 13.
The decision was taken in spite of opposition from the health group Médecins Sans Frontières (MSF). The group had filed a “patent opposition” to prevent Pfizer from getting a patent on its pneumococcal conjugate vaccine (PCV 13).
However, MSF has now warned that grant of the patent would block other manufacturers in India from supplying the vaccine to those who need it most.
Pneumococcal Conjugate Vaccine is used for?
• Pneumococcal Conjugate Vaccine is used for the prevention of pneumococcal pneumonia and invasive diseases caused by 13 Streptococcis pneumoniae strains.
• There are currently three types of PCV available on the global market, which go by the brand names: Prevnar, Synflorix and Prevnar 13.
About Pfizer Inc.
• Pfizer Inc. is an American pharmaceutical corporation headquartered in New York City.
• It is among the world's largest pharmaceutical companies.
• The company develops and produces medicines and vaccines for a wide range of medical disciplines, including immunology, oncology, cardiology, diabetology and neurology.
• The company was founded in 1849 by cousins Charles Pfizer and Charles F. Erhart in New York City as a manufacturer of fine chemicals.